Geistlich Pharma
Erik W. is a seasoned professional in the field of regulatory affairs, currently serving as a Senior Regulatory Affairs Manager at Geistlich Pharma AG since July 2019, after transitioning from a Regulatory Affairs Manager role. Prior experience includes a position at HARTMANN GROUP, where Erik held the roles of Regulatory Affairs Manager and R&D Manager between October 2016 and July 2019, and a brief tenure as a Masterstudent at Fraunhofer-Gesellschaft from September 2015 to May 2016. Erik W. holds a Master of Science (M.Sc.) in Funktionswerkstoffe from The Julius Maximilians University of Würzburg, earned between 2013 and 2016, and a Bachelor of Science (B.Sc.) in Nanotechnologie from FAU Erlangen-Nürnberg, completed in 2013.
This person is not in any offices
Geistlich Pharma
1 followers
Geistlich Pharma AG develops, produces and distributes medical devices and drugs (anti-infectives, vitamins) for regenerative medicine at the Wolhusen and Root sites in central Switzerland. The Swiss company forms part of the Geistlich group which has been in family hands since 1851. Geistlich Pharma and its three business units Geistlich Biomaterials, Geistlich Surgery and Geistlich Medical have ten subsidiaries and global distribution. Some 500 employees work for the company around the world. The company is a world leader in regenerative dentistry through its business unit Geistlich Biomaterials. The ownership structure enables the company to plan long-term and to consistently develop innovative products. Geistlich Pharma AG continuously invests in developing its research and technology and relies on its qualified and specialized employees. Currently Geistlich Pharma is - the global market leader in regenerative dentistry - the leader in biological bone and cartilage regeneration - supplies drugs and medical devices in selected application areas